REMUUN
Über das Unternehmen
The development of monoclonal antibody (mAb) therapies is a cornerstone of modern medicine, revolutionizing treatment across diverse disease areas. The field has a market value of CHF 300 billion per annum:Problem: Current antibody development is slow, expensive, and limits therapeutic potential. Understanding and harnessing the natural antibody editing mechanism (AID) could revolutionize this process.Solution: We've developed MEGA, the first modular AID-base editor. It mimics the full power of natural antibody gene modification, opening doors for faster, cheaper, and highly targeted antibody therapies.Proof: We've already optimized a clinical-grade antibody in just one week; a feat impossible with traditional methods.Value Proposition: Imagine new mAb therapies fast & precisely.